Nymox Pharmaceutical News (NASDAQ:NYMX)

DateTimeSource
Headline
08/24/201612:19PMGLOBENymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
HASBROUCK HEIGHTS, N.J., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage... More...>>
08/17/201610:00AMGLOBENymox Announces Private Placements of $2.24 Million
HASBROUCK HEIGHTS, N.J., Aug. 17, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million. The investments totaled 965,649 shares at an average price of $2.32 with no warrants... More...>>
08/11/201610:28AMGLOBENymox Announces Prostate Drug Progress
HASBROUCK HEIGHTS, N.J., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate... More...>>
08/11/20165:00AMPRNUSNymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Miscondu...
Nymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Misconduct By The Company PR Newswire BOSTON, Aug. 11, 2016 BOSTON, Aug. 11, 2016 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide... More...>>
08/10/201610:25PMBWIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corp. & Advises Investors with Lo...
Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) (Nasdaq: NYMX) concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire... More...>>
08/10/20164:53PMPRNUSSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nymox Pharmaceutical Corporation - NYMX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nymox Pharmaceutical Corporation - NYMX PR Newswire NEW YORK, Aug. 10, 2016 NEW YORK, Aug. 10, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nymox Pharmaceutical Corporation ("Nymox" or the "Company... More...>>
08/10/20163:59PMPRNUSSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX) PR Newswire NEW YORK, Aug. 10, 2016 NEW YORK, Aug. 10, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers... More...>>
08/10/201612:36PMBWEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Nymox Pharmaceutical Corporation
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) resulting from allegations that Nymox may have issued materially misleading business information to the investing public. On August 10... More...>>
06/22/20169:30AMGLOBENymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without C...
HASBROUCK HEIGHTS, N.J., June 22, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today results from the Company's 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Company's lead drug fexapotide. Men who received fexapotide showed a major... More...>>
02/09/201610:00AMGLOBENymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study
HASBROUCK HEIGHTS, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study successfully met... More...>>
02/04/201611:15AMGLOBENymox Announces Additional $2.1 Million Equity Financing
HASBROUCK HEIGHTS, N.J., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today private placement equity investment of US$2.1 Million. The investment was at $2.00 per share with no warrants. The investment was made by long-term Nymox shareholders. The Company has now... More...>>
12/31/20154:45PMGLOBENymox Files Current Financial Statements
HASBROUCK HEIGHTS, N.J., Dec. 31, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements. The financial results are available at - http://www.sec.gov/cgi-bin/browse-edgar?company=nymox&owner=exclude&action=getcompany... More...>>
12/17/20159:00AMGLOBENymox Provides Update From Shareholders Annual General Meeting December 16
HASBROUCK HEIGHTS, N.J., Dec. 17, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report an update on the Corporation's business as of December 16, 2015. At the Company's AGM in Nassau, the following highlights were presented: The Company is moving forward with the activities of preparing... More...>>
10/29/201510:31AMGLOBENymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer
HASBROUCK HEIGHTS, N.J., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reported today that long-term randomized cross-over data from the Company's  trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls... More...>>
10/08/201511:00AMGLOBENymox Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments
HASBROUCK HEIGHTS, N.J., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that that participants in prostate cancer clinical trial NX03-0040 had neared completion of the study's 18 month post-treatment assessments. The results from this 18 month study are expected to be reported... More...>>
09/22/20158:12AMPRNUSTechnical Coverage On Stocks From Diverse Sectors -- Bill Barrett, Nymox Pharmaceutical, GoPro, Mondelez International, and T...
Technical Coverage On Stocks From Diverse Sectors -- Bill Barrett, Nymox Pharmaceutical, GoPro, Mondelez International, and Tesla Motors PR Newswire NEW YORK, September 22, 2015 NEW YORK, September 22, 2015 /PRNewswire/ -- ACI Association has initiated research coverage on the following equities: Bill Barrett Corp (NYSE:... More...>>
05/15/20155:32PMGLOBENymox Reports First Quarter 2015 Financial Results
HASBROUCK HEIGHTS, N.J., May 15, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards. Nymox reported a net income of $1,576,551, or $0.04 per share for the quarter... More...>>
04/20/201510:00AMGLOBENymox Announces New Prostate Cancer Clinical Trial Results
HASBROUCK HEIGHTS, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. The new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years... More...>>
04/01/201510:00AMGLOBENymox Announces Phase 3 BPH Studies
HASBROUCK HEIGHTS, N.J., April 1, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the Company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH). This will include new long-term data from Studies NX02-0017 and NX02-0018... More...>>
03/31/20152:30PMGLOBENymox Reports 2014 Financial Results
HASBROUCK HEIGHTS, N.J., March 31, 2015 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2014 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,594,093, or $0.13 per share for the... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20160826 23:24:58